PCN26 QUANTIFYING THE RELATIVE CLINICAL VALUE OF NIVOLUMAB PLUS IPILIMUMAB VS. SUNITINIB IN FIRST-LINE ADVANCED OR METASTATIC RENAL CELL CARCINOMA WITH THE NUMBER NEEDED TO TREAT AND NUMBER NEEDED TO HARM IN SPAIN AND PORTUGAL
Nov 1, 2019, 00:00
10.1016/j.jval.2019.09.223
https://www.valueinhealthjournal.com/article/S1098-3015(19)32601-4/fulltext
Title :
PCN26 QUANTIFYING THE RELATIVE CLINICAL VALUE OF NIVOLUMAB PLUS IPILIMUMAB VS. SUNITINIB IN FIRST-LINE ADVANCED OR METASTATIC RENAL CELL CARCINOMA WITH THE NUMBER NEEDED TO TREAT AND NUMBER NEEDED TO HARM IN SPAIN AND PORTUGAL
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(19)32601-4&doi=10.1016/j.jval.2019.09.223
First page :
Section Title :
Open access? :
No
Section Order :
10170